Voloridge Investment Management LLC lessened its stake in NovoCure Limited (NASDAQ:NVCR - Free Report) by 15.4% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 870,155 shares of the medical equipment provider's stock after selling 158,270 shares during the quarter. Voloridge Investment Management LLC owned 0.80% of NovoCure worth $25,931,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. GeoWealth Management LLC acquired a new stake in NovoCure in the fourth quarter valued at approximately $27,000. Lindbrook Capital LLC increased its position in shares of NovoCure by 189.2% in the 4th quarter. Lindbrook Capital LLC now owns 1,854 shares of the medical equipment provider's stock valued at $55,000 after purchasing an additional 1,213 shares during the last quarter. Blue Trust Inc. raised its holdings in shares of NovoCure by 70.7% in the 4th quarter. Blue Trust Inc. now owns 1,886 shares of the medical equipment provider's stock valued at $56,000 after purchasing an additional 781 shares in the last quarter. SBI Securities Co. Ltd. purchased a new stake in shares of NovoCure during the 4th quarter worth $70,000. Finally, Nisa Investment Advisors LLC lifted its position in shares of NovoCure by 57.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,321 shares of the medical equipment provider's stock worth $129,000 after purchasing an additional 1,575 shares during the last quarter. 84.61% of the stock is owned by institutional investors and hedge funds.
NovoCure Stock Down 2.5%
NovoCure stock opened at $17.75 on Thursday. The company has a market capitalization of $1.98 billion, a P/E ratio of -12.68 and a beta of 0.73. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.44 and a current ratio of 1.49. NovoCure Limited has a fifty-two week low of $14.17 and a fifty-two week high of $34.13. The stock has a 50-day simple moving average of $17.57 and a 200-day simple moving average of $21.80.
NovoCure (NASDAQ:NVCR - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The medical equipment provider reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.47) by $0.16. The company had revenue of $154.99 million during the quarter, compared to analysts' expectations of $147.57 million. NovoCure had a negative return on equity of 41.48% and a negative net margin of 25.93%. The firm's revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.36) earnings per share. Equities research analysts expect that NovoCure Limited will post -1.3 earnings per share for the current year.
Analysts Set New Price Targets
A number of research firms have weighed in on NVCR. JPMorgan Chase & Co. cut their price target on NovoCure from $29.00 to $28.00 and set a "neutral" rating on the stock in a research note on Thursday, April 10th. Piper Sandler dropped their price objective on NovoCure from $42.00 to $34.00 and set an "overweight" rating on the stock in a report on Wednesday, April 23rd. Wedbush decreased their target price on NovoCure from $29.00 to $27.00 and set a "neutral" rating for the company in a research note on Wednesday, April 16th. Finally, StockNews.com lowered shares of NovoCure from a "hold" rating to a "sell" rating in a research note on Friday, April 25th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, NovoCure presently has an average rating of "Hold" and an average price target of $32.83.
Read Our Latest Report on NVCR
NovoCure Company Profile
(
Free Report)
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua.
See Also
Want to see what other hedge funds are holding NVCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NovoCure Limited (NASDAQ:NVCR - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider NovoCure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NovoCure wasn't on the list.
While NovoCure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
